紫杉醇联合卡铂治疗30例晚期卵巢上皮性癌  

Combination chemotherapy with paclitaxel and carboplatin in 30 patients with advanced epithelial ovarian cancer

作　　者：沈蓉[1] 蔡华蕾[1] 陈晓玲[1] 

机构地区：[1]贵阳医学院附属医院,贵州550004

出　　处：《安徽医学》2006年第4期303-305,共3页Anhui Medical Journal

摘　　要：目的评价对晚期卵巢上皮性癌患者术后行紫杉醇静脉和卡铂腹腔灌注联合化疗的疗效及毒副反应。方法晚期卵巢上皮性癌30例行肿瘤细胞减灭术后．采用TC方案化疗，紫杉醇135mg／m^2全身化疗，卡铂350～400mg／m^2腹腔灌注化疗，3～4周1疗程，常规行6个疗程，在6个月内完成。结果Ⅲ期总有效率73．08％，Ⅳ期为50．00％。毒副反应主要为骨髓抑制，发生率达73％，但63％为Ⅰ～Ⅱ度，胃肠道反应，肝功损害，周围神经炎，肾功损害，心脏毒性发生率分别为57％、17％、20％、13％、3％，多为Ⅰ～Ⅱ度。所有患者均未因毒副作用中断或退出治疗。结论TC方案联合化疗效果好，毒副反应轻，适合于对其他化疗反应大、有潜在心、肝、肾功能不良或年老体弱、多次化疗后、恶性度高的患者。Objective To evaluate the efficacy and toxicity of cytoreductive surgery plus combination chemotherapy with paclitaxel （intravenous infusion） and carboplatin （intraperitoneal chemotherapy） in patients with advanced ovarian cancer. Methods 30 patients admitted to our hospital for primary treatment, All patients with advanced epithelial ovarian cancer were given cytoreductive surgery. Regimens were TC（paclitaxel, carboplatin）Results objective response rate （RR） ：73.08% with stage 111 and 50.00% with stage Ⅳ. 73% experienced WHO grade Ⅰ--Ⅳ bone marrow suppression, which was the most common and serious toxicity. WHO grade Ⅰ-Ⅱ side effect of gastrointestinal tract, liver,peripheral neuropathy, kidney and heart occurred in 57%, 17 0%, 20%, 13% and 3% of patients, respectively. No patient＇s withdrew because of treatment related toxicity. Conclusion our data suggest that the combination of paelitaxel and carboplatin has promising therapeutic activity in patients with advanced epithelial ovarian cancer： This regimen shows good efficacy and an acceptable safety profile and may prove to be a suitable alternative regimen in this indication,especially for the patient with bad function of the heart, liver and kidney or old, physically weak patients.

关 键 词：卵巢上皮性癌 卡铂 紫杉醇 化疗 

分 类 号：R737.31[医药卫生—肿瘤] R734.2[医药卫生—临床医学]